A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors

Date 26 September 2015
Event European Cancer Congress 2015
Session Early Drug Development I
Topics Drug Development
Presenter De Weger, V.